Overdiagnosis of melanoma: causes, consequences and solutions
Malignant melanoma is the skin tumor that causes most deaths in Germany. At an early stage, melanoma is well treatable, so early detection is essential. However, the skin cancer screening program in Germany has been criticized because although melanomas have been diagnosed more frequently since intr...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
25 August 2020
|
| In: |
Journal der Deutschen Dermatologischen Gesellschaft
Year: 2020, Volume: 18, Issue: 11, Pages: 1236-1243 |
| ISSN: | 1610-0387 |
| DOI: | https://doi.org/10.1111/ddg.14233 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/https://doi.org/10.1111/ddg.14233 Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/ddg.14233 
|
| Author Notes: | Heinz Kutzner, Tanja B. Jutzi, Dieter Krahl, Eva I. Krieghoff‐Henning, Markus V. Heppt, Achim Hekler, Max Schmitt, Roman C.R. Maron, Stefan Fröhling, Christof von Kalle, Titus J. Brinker |
| Summary: | Malignant melanoma is the skin tumor that causes most deaths in Germany. At an early stage, melanoma is well treatable, so early detection is essential. However, the skin cancer screening program in Germany has been criticized because although melanomas have been diagnosed more frequently since introduction of the program, the mortality from malignant melanoma has not decreased. This indicates that the observed increase in melanoma diagnoses be due to overdiagnosis, i.e. to the detection of lesions that would never have created serious health problems for the patients. One of the reasons is the challenging distinction between some benign and malignant lesions. In addition, there may be lesions that are biologically equivocal, and other lesions that are classified as malignant according to current criteria, but that grow so slowly that they would never have posed a threat to patient’s life. So far, these “indolent” melanomas cannot be identified reliably due to a lack of biomarkers. Moreover, the likelihood that an in-situ melanoma will progress to an invasive tumor still cannot be determined with any certainty. When benign lesions are diagnosed as melanoma, the consequences are unnecessary psychological and physical stress for the affected patients and incurred therapy costs. Vice versa, underdiagnoses in the sense of overlooked melanomas can adversely affect patients’ prognoses and may necessitate more intense therapies. Novel diagnostic options could reduce the number of over- and underdiagnoses and contribute to more objective diagnoses in borderline cases. One strategy that has yielded promising results in pilot studies is the use of artificial intelligence-based diagnostic tools. However, these applications still await translation into clinical and pathological routine. |
|---|---|
| Item Description: | Gesehen am 04.02.2021 |
| Physical Description: | Online Resource |
| ISSN: | 1610-0387 |
| DOI: | https://doi.org/10.1111/ddg.14233 |